Momentum For ViroMed's Gene Therapy After ‘Exceptional’ Trial Go-Ahead In China

China FDA has granted earlier-than-expected approval to begin a Phase III clinical trial of ViroMed's gene therapy VM202. Successful trials in China are expected to support global commercialization of the first-in-class therapy for cardiovascular and neurological diseases, which is also in late-stage clinical development in the US.